EN DE
Watch Qilian International Holding Group Limited for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Qilian International Holding Group Limited (BGM) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Qilian International Holding Group Limited stock $10.17, price $8.01, upside +27.0%, quality 26 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · Based in China · ISIN KYG7307E1237

QI Qilian International Holding Group Limited logo Thin data Nov 10, 2026

Qilian International Holding Group Limited

BGM · US
Fairly valued, weak quality

The stock costs 21% less than our calculation considers fair.

Revenue last quarter +70% vs. a year ago.
Fair value $10.17 · Fairly valued
Quality 26/100
Weak Growth (revenue 5y −5.4 %/yr in USD)
Loss-making · -44.2% net margin (TTM)
Negative free cash flow
Trails peers (3/9)
Narrow moat 17/100
Thin data
Estimate
Watch Qilian International Holding Group Limited for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$624.46 $2.81 Fair Value $10.17 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $2.81 – $624.46 · fair‑value band $7.63 – $12.72 · the $8.01 price screens below the $10.17 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Qilian International Holding Group in your weekly email

Every Wednesday you see whether Qilian International Holding Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China.

Show moreShow less

It offers oxytetracycline products, including Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline active pharmaceutical ingredients, which are used by pharmaceutical companies in the manufacturing of medications that use oxytetracycline as an active ingredient.

The company also provides licorice products, such as Gan Di Xin, a medicine made from raw licorice materials; Qilian Shan licorice extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, an ingredient for medical preparation companies to produce compound licorice oral solutions.

In addition, it offers traditional Chinese medicine derivatives products comprising Ahan antibacterial paste that is used to treat refractory chronic skin diseases; heparin products, including heparin sodium preparation, an ingredient for pharmaceutical companies to produce medications used in treating cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and sausage casings, such as Zhu Xiaochang sausage casings for culinary purposes.

Further, the company provides Fertilizer products comprising Xiongguan organic fertilizers to improve crop yield, increase soil's chemical properties, and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers for plant growth.

Additionally, it focuses on the AI-driven commercialization of DuXiaoBao platform. BGM Group Ltd. is based in Chengdu, China.

Stock analysis

Qilian International Holding Group Limited (BGM) currently trades at $8.01, while our estimate is $10.17, so the stock looks roughly fairly valued today (gap 21.2%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $7.63 (bear) to $12.72 (bull), the price of $8.01 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 26/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Qilian International Holding Group Limited reported revenue of $37.9M in FY2025 versus $57.1M in FY2021, a compound −9.7%/yr. Reported net income was −$19.9M in FY2025.

Key figures

Market cap $120M Micro · P/S ratio 2.51 · EPS (TTM) $−5.15 · Net margin −52.6% · Return on equity −7.4% · Return on assets (EBIT) −0.5% (5-year average) · Operating margin −3.6% · Revenue (TTM) $47.9M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 17 out of 100 (medium confidence).

What moves the price

The share trades about 97% below its 52-week high and 11% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 27%, BGM screens cheaper than that median.

Fair Value

Bear $7.63 Fair Value $10.17 Bull $12.72
Price $8.01 · Upside +27.0%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 26/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 29
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 60
Debt, balance sheet and risk of trouble
Investment 27
Does it invest with discipline instead of growing at any price?
Low Volatility 13
How calm the share price moves, does not count
Price momentum 21
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 50
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 6/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+51.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−16.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.4%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
9.6% (2020) → −33.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch BGM, get fair value alerts →

Compare Qilian International Holding Group Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 606 stocks

Beats the industry median on 3/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 26 · Bottom 25%
Fair Value upside +27.0% · Top 25%
Profitability
Return on assets −4.6% · Bottom 25%
Net margin (12 months) −44.2% · Bottom 25%
Operating margin (12 months) −3.6% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 69.8% · Top 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 0.31× · Cheapest 25%
P/S (12 months) 2.51× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)69 · sector 18
FUTURE (revenue growth)100 · sector 25
PAST (return on equity)0 · sector 25
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 31

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $82.46 $113.53 +38% vs BGM
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥48.55 ¥55.21 +14% vs BGM
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,905 ₹1,983 +4% vs BGM
Haleon plc HLN $9.06 $8.62 −5% vs BGM
Merck KGaA MRK €149.35 €109.18 −27% vs BGM
Galderma Group GALD CHF 188.55 CHF 109.80 −42% vs BGM
Takeda Pharmaceutical Company TAK $20.93 $11.34 −46% vs BGM
Teva Pharmaceutical Industries Limited TEVA $42.40 $20.74 −51% vs BGM
Sandoz Group SDZ CHF 83.38 CHF 39.70 −52% vs BGM
Divi's Laboratories Limited DIVISLAB ₹11,566 ₹1,567 −86% vs BGM

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Qilian International Holding Group Limited: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Qilian International Holding Group Limited Fair Value". https://www.fairvalue-calculator.com/stock/BGM

Frequently asked questions

Is Qilian International Holding Group Limited (BGM) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $10.17 versus a price of $8.01, about +27% upside (fairly valued).
What is the fair value of BGM?
Our estimate for Qilian International Holding Group Limited is $10.17 (as of Nov 10, 2026), built from audited fundamentals. The current price: $8.01.
What is the quality score of BGM?
Qilian International Holding Group Limited has a Quality Score of 26/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Qilian International Holding Group Limited (BGM)?
Our calculated price target is the estimate of $10.17 (as of Nov 10, 2026). Cautious scenario $7.63, optimistic scenario $12.72. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Qilian International Holding Group Limited stock forecast for 2026?
Our estimate puts fair value at $10.17, about +27% upside versus a price of $8.01 (fairly valued). Cautious scenario $7.63, optimistic scenario $12.72. The calculation is refreshed regularly with new filings.
What is the revenue of Qilian International Holding Group Limited (BGM)?
Qilian International Holding Group Limited reported trailing-twelve-month revenue of about $47.9M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Qilian International Holding Group Limited (BGM)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Qilian International Holding Group Limited it is $10.17 per share (as of Nov 10, 2026), against a price of $8.01.
Is Qilian International Holding Group Limited stock overvalued or undervalued in 2026?
As of Nov 10, 2026, BGM trades below its calculated fair value: price $8.01, fair value $10.17, a gap of about +27% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BGM?
No. The price is what the market pays today ($8.01); the fair value is what the company's own numbers justify ($10.17). For Qilian International Holding Group Limited the two are $2.16 per share apart. That gap is exactly why we show both numbers side by side.
How much is Qilian International Holding Group Limited worth?
The market values Qilian International Holding Group Limited at about $120M (market capitalisation, as of Nov 10, 2026). Per share that is $8.01; our models calculate a fair value of $10.17 per share.
What do the bullish and bearish scenarios say about BGM?
Our models span a range for Qilian International Holding Group Limited: cautious scenario $7.63, base $10.17, optimistic $12.72 per share (as of Nov 10, 2026, price $8.01). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Qilian International Holding Group Limited (BGM)?
Balance-sheet figures for Qilian International Holding Group Limited (as of Nov 10, 2026): return on equity −7.4%. They feed the Quality Score of 26/100, which measures business quality independently of the share price.
How far is BGM from its 52-week high?
Qilian International Holding Group Limited trades at $8.01, about 97% below its 52-week high of $287.22 and 11% above the low of $7.20 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $10.17 is for.
Which stocks are comparable to Qilian International Holding Group Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Qilian International Holding Group Limited stock attractive at the current price?
The data as of Nov 10, 2026: price $8.01, calculated fair value $10.17 (+27%), Quality Score 26/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Qilian International Holding Group Limited currently trades 21% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Qilian International Holding Group Limited (BGM)?
The closing price on Nov 10, 2026 was $8.01. Our estimate is $10.17, about +27% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Qilian International Holding Group Limited right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Qilian International Holding Group Limited

How large is the market capitalisation of Qilian International Holding Group Limited (BGM)?
The market capitalisation of Qilian International Holding Group Limited is $120M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Qilian International Holding Group Limited (BGM)?
The price-to-sales ratio of Qilian International Holding Group Limited is 2.51 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Qilian International Holding Group Limited (BGM)?
Earnings per share at Qilian International Holding Group Limited are $−5.15. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Qilian International Holding Group Limited (BGM)?
The net margin of Qilian International Holding Group Limited is −52.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Qilian International Holding Group Limited (BGM)?
The return on equity (ROE) of Qilian International Holding Group Limited is −7.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Qilian International Holding Group Limited (BGM)?
On an EBIT basis the return on assets of Qilian International Holding Group Limited is −0.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Qilian International Holding Group Limited (BGM)?
The operating margin of Qilian International Holding Group Limited is −3.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Qilian International Holding Group Limited (BGM)?
Revenue at Qilian International Holding Group Limited is growing +69.8% versus a year earlier (3y avg −16.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Qilian International Holding Group Limited (BGM) generate?
The free cash flow of Qilian International Holding Group Limited is −$4.4M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Qilian International Holding Group Limited (BGM) hold?
Qilian International Holding Group Limited holds more cash than debt, $7.9M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Qilian International Holding Group Limited in the live analysis

One click puts Qilian International Holding Group Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.